TNFRSF17 and AL amyloidosis: In preclinical studies, anti-BCMA-CAR-T therapy showed low antigen-independent signaling and potent in vitro killing of myeloma tumor cells, across a range of BCMA expression levels, as well as sustained elimination of tumors and 100% survival, after single-dose administration in a mouse model of human multiple myeloma [12].